CLINICAL TRIALS PROFILE FOR CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE
✉ Email this page to a colleague
All Clinical Trials for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00774280 ↗ | Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen | Completed | Cooperative Study Group A for Hematology | Phase 3 | 2002-05-01 | 1. At the same time of registration, patients will be randomized to one of the two conditioning therapy groups; Arm I (intravenous busulfan plus cyclophosphamide; BuCy) or Arm II (intravenous busulfan plus fludarabine; BuFlu). 2. Randomization will be a stratified permuted-block design. 2.1The patients will be stratified into standard risk vs. high risk group, and related vs. unrelated donor. Standard risk group will be defined as follows: patients with acute leukemia in first remission, CML in chronic phase, and MDS (RA or RARS categories). High risk group will be defined as follows: patients with acute leukemia in relapse or in second or subsequent remission, CML in accelerated or blastic phase, and MDS (CMMoL or RAEB categories). 2.2.Pre-assigned block size is 8. |
NCT00980876 ↗ | A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension | Completed | Pharmagenix Projetos em Medicina Farmacêutica Ltda. | Phase 3 | 2012-04-01 | The objective of this study is to compare the efficacy and safety profiles of the test product containing 2 mg/mL ciprofloxacin hydrochloride associated with 10 mg/mL of hydrocortisone with the reference product Cipro HC®, in patients with acute otitis externa. |
NCT00980876 ↗ | A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension | Completed | Farmoquimica S.A. | Phase 3 | 2012-04-01 | The objective of this study is to compare the efficacy and safety profiles of the test product containing 2 mg/mL ciprofloxacin hydrochloride associated with 10 mg/mL of hydrocortisone with the reference product Cipro HC®, in patients with acute otitis externa. |
NCT02017197 ↗ | Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil | Completed | Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 | 2014-08-01 | The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks. |
NCT02017197 ↗ | Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil | Completed | Federal University of São Paulo | Phase 4 | 2014-08-01 | The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE
Condition Name
Clinical Trial Locations for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE
Clinical Trial Progress for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE
Clinical Trial Phase
Clinical Trial Sponsors for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE
Sponsor Name